New Phase 3 trial: A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) — Merck Sharp & Dohme LLC
Why now
Thesis: Pipeline expansion optionality, no near-term catalyst
Catalyst to watch: First patient enrolled and trial timeline updates
Main risk: HFpEF endpoint failures are common in Phase 3
Why it matters
A Phase 3 readout for sotatercept in HFpEF-related pulmonary hypertension would extend the drug beyond PAH, but not-yet-recruiting status means no near-term data.
Details
Sponsor: Merck Sharp & Dohme LLC; Status: Not Yet Recruiting; Conditions: Pulmonary Hypertension; Interventions: Sotatercept, Placebo; Enrollment: 352 (estimated); First posted: 2026-09-24; NCT: NCT07839585
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-24 12:00 UTC